Efficacy of different anti-vascular endothelial growth factor drugs in the treatment of diabetic macular edema and their relationship with optical coherence tomography classification
10.3980/j.issn.1672-5123.2023.6.22
- VernacularTitle:不同抗VEGF药物治疗糖尿病性黄斑水肿的疗效及其与OCT分型的关系
- Author:
Tao TIAN
1
,
2
;
Xiao-Xi YAO
1
,
2
;
Jing-Li PENG
1
,
2
;
Zhi-Yuan LI
1
,
2
;
Gang-Hua FENG
1
,
2
;
Ru LIU
1
,
2
;
Xiao-Ping ZHOU
1
,
2
;
Yuan YANG
1
,
2
;
Guo-Ping KUANG
1
,
2
Author Information
1. Department of Ophthalmology
2. Hunan Provincial Key Laboratory of Medical Imaging Artificial Intelligence, Xiangnan University, Chenzhou 423099, Hunan Province, China
- Publication Type:Journal Article
- Keywords:
diabetic macular edema;
anti-vascular endothelial growth factor(VEGF)drugs;
optical coherence tomography(OCT)classification;
efficacy
- From:
International Eye Science
2023;23(6):991-995
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To explore the clinical efficacy of different anti-vascular endothelial growth factor(VEGF)drugs in the treatment of diabetic macular edema(DME), and analyze their relationship with optical coherence tomography(OCT)classification.METHODS: A total of 45 DME patients treated with ranibizumab(admitted to our hospital from February 2020 to February 2022)were selected as the ranibizumab group, and 45 DME patients treated with conbercept during the same period were selected as the conbercept group. The ranibizumab group was treated with retinal photocoagulation combined with ranibizumab, and the conbercept group was treated with retinal photocoagulation combined with conbercept. The improvement of symptoms(improvement time of macular edema, time of retinal thickness returning to normal, disappearance time of neovascularization and absorption time of fundus hemorrhage), levels of serum interleukin-6(IL-6)and VEGF, central macular thickness(CMT), best corrected visual acuity(BCVA), and complications were compared between the two groups, and the relationship between their clinical efficacy and different OCT types were analyzed.RESULTS: There was no significant difference in the improvement time of macular edema, time of retinal thickness returning to normal, disappearance time of neovascularization and absorption time of fundus hemorrhage between the two groups(P>0.05); After treatment, the values of IL-6, VEGF and BCVA in the two groups were significantly lower than those before treatment(P<0.01), but there was no significant difference between the two groups(P>0.05); compared with before treatment, CMT was significantly decreased in both groups after treatment(P<0.05), and compared with ranibizumab group, the CMT was significantly decreased in the conbercept group(P<0.01); there was no significant difference in the incidence of complications between two groups(P>0.05); there were significant differences in the total effective rate among patients with serous retinal detachment(SRD), cystoid macular edema(CME)and diffuse retinal thickening(DRT; P<0.05), among which DRT had the highest total effective rate and SRD had the lowest total effective rate.CONCLUSION: Both conbercept and ranibizumab in the treatment of DME can effectively improve the clinical symptoms of patients and reduce the inflammatory response, but conbercept can better reduce the level of CMT, and has better treatment effect on DRT-type DME patients.
